Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
NCT01579084
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class
Conditions
Rosacea
Erythema
Interventions
DRUG:
AGN-199201 Formulation A
DRUG:
AGN-199201 Formulation B
DRUG:
AGN-199201 Formulation C
DRUG:
AGN-199201 Vehicle
Sponsor
Allergan